Literature DB >> 8006977

Effects of adriamycin on ionic currents in single cardiac myocytes of the rabbit.

Y E Earm1, W K Ho, I So.   

Abstract

Adriamycin has been widely used as an anticancer drug, but its clinical use is limited by a dose-dependent cardiac toxicity. Proposed mechanisms for the adriamycin-induced cardiomyopathy include increasing the Ca current, inhibiting the Na/Ca exchange and dysfunction of the sarcoplasmic reticulum (SR). Using the whole cell voltage clamp technique in single isolated atrial and ventricular myocytes of the rabbit, we have investigated the effect of adriamycin on various current systems which are related to regulating intracellular Ca concentration: the Ca current, the Na/Ca exchange current and [Ca2+]i-dependent currents (ouabain-induced transient inward current and the inward tail current). Adriamycin, 0.05 mg/ml, increased Ca current (L-type) by 61%. Adriamycin inhibited the inward tail current in a dose-dependent manner between 0.02 and 0.1 mg/ml and when low concentration was used the effect was reversible. Ouabain-induced transient inward current was also suppressed by 0.05 mg/ml adriamycin. Na/Ca exchange current which is partly responsible for inducing [Ca2+]i-dependent currents was, however, not affected by adriamycin, suggesting that the effect adriamycin on [Ca2+]i-dependent currents is due to inhibition of SR function. From these results it is suggested that the increase of Ca current and inhibition of SR function cause adriamycin-induced cardiac toxicity: SR dysfunction not only causes a decrease of myocardial contractility, it can also accelerate the Ca overload process which might originate from the increase of Ca current.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8006977     DOI: 10.1006/jmcc.1994.1019

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  7 in total

1.  Fura-2 fluorescent technique for the assessment of Ca2+ homeostasis in cardiomyocytes.

Authors:  Y J Xu; Q Shao; N S Dhalla
Journal:  Mol Cell Biochem       Date:  1997-07       Impact factor: 3.396

Review 2.  Cardiotoxicity in childhood cancer survivors: strategies for prevention and management.

Authors:  Danielle Harake; Vivian I Franco; Jacqueline M Henkel; Tracie L Miller; Steven E Lipshultz
Journal:  Future Cardiol       Date:  2012-07

3.  Astragaloside IV inhibits adriamycin-induced cardiac ferroptosis by enhancing Nrf2 signaling.

Authors:  Li-Fei Luo; Peng Guan; Lu-Yun Qin; Jian-Xin Wang; Na Wang; En-Sheng Ji
Journal:  Mol Cell Biochem       Date:  2021-03-03       Impact factor: 3.396

Review 4.  Cancer chemotherapy and cardiac arrhythmias: a review.

Authors:  Juan Tamargo; Ricardo Caballero; Eva Delpón
Journal:  Drug Saf       Date:  2015-02       Impact factor: 5.606

Review 5.  Molecular and cellular mechanisms of cardiotoxicity.

Authors:  Y J Kang
Journal:  Environ Health Perspect       Date:  2001-03       Impact factor: 9.031

6.  Mechanism of doxorubicin cardiotoxicity evaluated by integrating multiple molecular effects into a biophysical model.

Authors:  M Fernandez-Chas; M J Curtis; S A Niederer
Journal:  Br J Pharmacol       Date:  2018-01-23       Impact factor: 8.739

7.  Rates and risk of arrhythmias in cancer survivors with chemotherapy-induced cardiomyopathy compared with patients with other cardiomyopathies.

Authors:  Michael G Fradley; Federico Viganego; Kevin Kip; Angel Martin; Aarti A Patel; Roohi Ismail-Khan; Sanders Chae; Bengt Herweg; Arthur Labovitz
Journal:  Open Heart       Date:  2017-12-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.